CJC-1295 & Ipamorelin Blend (10MG)

What Is the CJC-1295 & Ipamorelin Blend and Why Buy It for Research?

Buy CJC-1295 & Ipamorelin Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and metabolic regulation. Specifically, this 10mg research formulation combines two complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: CJC-1295 (Mod GRF 1-29, 5mg) and Ipamorelin (5mg). This blend pairs a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue (GHS) to probe convergent pathways in the GH-IGF-1 axis.

CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that engages the GHS-R1a receptor through Gq/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. Importantly, Ipamorelin is uniquely selective in its action—it stimulates GH release with negligible cortisol or prolactin elevation. Furthermore, when combined, these two peptides produce synergistic GH release—significantly higher than either compound alone. Moreover, Core Peptides supplies this blend as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy CJC-1295 & Ipamorelin Blend in Switzerland.

CJC-1295 & Ipamorelin Blend Research Overview: Buy CJC-1295 & Ipamorelin Blend in Switzerland for GH Axis Studies

Centrally, research into the CJC-1295 and Ipamorelin blend has focused on the complementary and synergistic mechanisms of its two components. Researchers established the foundational observation that GHRH + GHRP produces synergistic GH release in human subjects, demonstrating that co-administration of GHRH and GHRP produced GH peaks significantly higher than either peptide alone.

CJC-1295 (Mod GRF 1-29) functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. Importantly, the peptide incorporates four strategic amino acid substitutions at positions 2 (Ala to D-Ala), 8 (Asn to Gln), 15 (Gly to Ala), and 27 (Met to Leu), which confer resistance to DPP-IV cleavage and other degradation pathways, extending the biological half-life to approximately 30 minutes. The D-Ala substitution at position 2 is the most critical modification, as native GHRH is rapidly inactivated by DPP-IV, which cleaves the Tyr1-Ala2 peptide bond. Consequently, this single modification extends the biological half-life from less than 7 minutes (native GHRH) to approximately 30 minutes.

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It mimics ghrelin and binds to the ghrelin receptor (GHS-R1a) in the pituitary, thereby selectively stimulating the release of GH. Unlike other GH releasing peptides, Ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone, with negligible cortisol or prolactin elevation. This selectivity makes Ipamorelin a valuable tool for researchers seeking isolated GH effects without the confounding influences of adrenal axis activation.

When combined, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release with minimal cortisol or prolactin elevation. As a result, this dual combination amplifies GH output through convergent but mechanistically independent pathways. Accordingly, researchers who buy CJC-1295 & Ipamorelin Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and metabolic regulation.

How Does the CJC-1295 & Ipamorelin Blend Work in Research?

Mechanistically, the CJC-1295 and Ipamorelin blend operates through two complementary signaling pathways that converge on GH release from pituitary somatotrophs.

GHRH Receptor Pathway (CJC-1295)

CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog with a half-life of approximately 30 minutes. This binding initiates a downstream signaling cascade that results in GH synthesis and release. The form without DAC (Mod GRF 1-29) has a shorter half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH. Importantly, this stimulation preserves the body’s natural pulsatile GH release pattern and negative feedback regulation through IGF-1 and somatostatin, avoiding the supraphysiological, continuous GH elevation associated with exogenous recombinant GH administration.

GHS-R1a Pathway (Ipamorelin)

Ipamorelin binds the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, through Gq/11-coupled signaling, generating IP3 and DAG. Consequently, the resulting intracellular calcium mobilization triggers rapid exocytosis of pre-formed GH vesicles. Notably, Ipamorelin’s key distinguishing feature is its failure to significantly stimulate ACTH or cortisol release at GH-effective doses, suggesting preferential activation of specific downstream signaling branches. As a result, Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, making it valuable for studies requiring isolated GH effects.

Synergistic Effects

The dual combination produces synergistic (not merely additive) GH release. Specifically, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release. Ipamorelin works by activating GHS-R1a receptors on pituitary cells, triggering one specific signaling pathway (Gq/Gi G-protein coupled). At the same time, CJC-1295 works by activating GHRH receptors on the same pituitary cells, triggering a different signaling pathway (Gs G-protein coupled). When both pathways are activated simultaneously, the result is multiplicative—far greater than either pathway alone. Furthermore, Ipamorelin’s selective GH release profile with minimal cortisol elevation makes this blend a preferred choice for researchers seeking isolated GH effects without adrenal axis activation.

Why Is the CJC-1295 & Ipamorelin Blend Studied in Switzerland?

Primarily, researchers study this blend because it represents a well-characterized dual combination of complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and receptor pharmacology—with the added benefit of selective GH release. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.

Research has demonstrated the blend’s relevance across multiple domains. For instance, GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Furthermore, research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Additionally, Ipamorelin’s selective GH release profile with minimal cortisol elevation makes it valuable for studies requiring isolated GH effects without the confounding influences of adrenal axis activation. Ultimately, researchers who buy CJC-1295 & Ipamorelin Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and receptor pharmacology.

CJC-1295 & Ipamorelin Blend Research Areas in Laboratory Studies

Research Area	Focus	Key Components
GH Axis Signaling	Dual-pathway activation, GHRH/GHS receptor crosstalk, pulsatile secretion	Both (complementary pathways)
Metabolic Regulation	IGF-1 elevation, lipolysis, protein synthesis, metabolic homeostasis	Both (GH-dependent effects)
Receptor Pharmacology	GHRH-R, GHS-R1a binding, receptor binding kinetics, biased agonism	Both (distinct targets)
Selective GH Release	GH-specific effects, minimal cortisol/prolactin spillover, adrenal sparing	Ipamorelin
Pulsatile GH Secretion	Physiologic GH patterning, amplitude modulation, pulse dynamics	CJC-1295
Endocrine Research	Hormone profiling, cortisol/prolactin studies, adrenal axis sparing	Both

CJC-1295 & Ipamorelin Blend Compared With Related Research Formulations

Formulation	Components	Research Focus	Key Difference
CJC-1295 + Ipamorelin Blend	CJC-1295 (Mod GRF 1-29) + Ipamorelin (1:1)	GH axis, selective GH release, metabolic regulation	Weaker GH pulse; minimal cortisol/prolactin spillover
CJC-1295 + GHRP-2 Blend	CJC-1295 + GHRP-2	GH axis, synergistic release, metabolic regulation	Stronger GH release, more cortisol/prolactin elevation
CJC-1295 + GHRP-6 Blend	CJC-1295 + GHRP-6	GH axis, synergistic release, appetite modulation	Significant appetite stimulation via GHRP-6
CJC-1295 + Hexarelin Blend	CJC-1295 + Hexarelin	GH axis, cardioprotection	Hexarelin adds CD36 cardioprotection

Comparatively, the CJC-1295 and Ipamorelin blend differs from other GHRH/GHS combinations in its selectivity. On the one hand, Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation. On the other hand, other GHRPs such as GHRP-2, GHRP-6, and Hexarelin generate robust GH output alongside measurable increases in ACTH, cortisol, and prolactin. In contrast, the CJC-1295 and Ipamorelin blend is frequently chosen for its favorable selectivity profile, making it suitable for research applications requiring isolated GH effects without adrenal axis activation.

Research Applications for the CJC-1295 & Ipamorelin Blend in Switzerland

Scientists have investigated this peptide blend across several research domains:

• GH Axis Signaling Research: Researchers use this blend to study dual-pathway GH activation, GHRH/GHS receptor crosstalk, and pulsatile GH secretion dynamics.
• Metabolic Regulation Studies: The blend is employed to investigate IGF-1 elevation, lipolysis, protein synthesis, and metabolic homeostasis pathways.
• Receptor Pharmacology: The blend serves as a tool for studying GHRH-R and GHS-R1a binding, receptor binding kinetics, and biased agonism.
• Selective GH Release Studies: Ipamorelin’s selective GH profile with minimal cortisol elevation is investigated in endocrine research.
• Endocrine Research: The blend is used to study hormone profiling, cortisol/prolactin sparing, and adrenal axis sparing.
• Pulsatile GH Secretion: CJC-1295’s pulsatile GH patterning is studied in models of physiologic GH secretion.

Evidently, researchers who buy CJC-1295 & Ipamorelin Blend in Switzerland gain a valuable addition to any laboratory toolkit focused on GH axis signaling, metabolic research, and endocrine pharmacology.

CJC-1295 & Ipamorelin Blend Product Specifications

Specification	Details
Product Name	CJC-1295 & Ipamorelin Blend
Alternative Names	Mod GRF 1-29 + Ipamorelin, CJC-1295/Ipamorelin stack, GHRH/GHS blend
Total Content	10mg
Composition	CJC-1295 (Mod GRF 1-29) 5mg + Ipamorelin 5mg (1:1 ratio)
Form	Lyophilized powder
Purity	Not verified
CJC-1295 Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (29 amino acids)
CJC-1295 Molecular Weight	3,367.9 Da
CJC-1295 Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Ipamorelin Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 amino acids)
Ipamorelin Molecular Weight	711.85 Da
Ipamorelin Molecular Formula	C₃₈H₄₉N₉O₅
Ipamorelin CAS Number	170851-70-4
Research Category	Growth Hormone Peptides / Muscle & Performance
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and bacteriostatic water; reconstitute slowly

How to Evaluate CJC-1295 & Ipamorelin Blend Quality for Research

When sourcing this peptide blend for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the identity and molecular weight of each component peptide.
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity of each peptide, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results for each component.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, composition (5mg CJC-1295 + 5mg Ipamorelin), total content, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptide blends and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation for each component, purity percentages as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptides they are using in their laboratory investigations.

Storage and Stability of the CJC-1295 & Ipamorelin Blend

Core Peptides supplies this blend as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents (e.g., bacteriostatic water or sterile water)
• Inject solvent slowly against the inner wall of the vial rather than directly onto the powder; do not shake
• Gently roll the vial in a circular motion to dissolve
• Once reconstituted, refrigerate at 2°C to 8°C and utilize promptly
• Protect from light and moisture

Frequently Asked Questions About Buying the CJC-1295 & Ipamorelin Blend in Switzerland

What is the CJC-1295 & Ipamorelin Blend?

Specifically, this 10mg blend combines CJC-1295 (Mod GRF 1-29, 5mg) and Ipamorelin (5mg) in a 1:1 ratio. It pairs a GHRH analog with a selective growth hormone secretagogue for synergistic GH release research.

What is the blend researched for?

Primarily, researchers study this blend for its synergistic GH release, metabolic regulation, and selective GH release profile. It is most often discussed for GH axis signaling, endocrine research, and metabolic studies.

How does the blend work?

Mechanistically, CJC-1295 activates the GHRH receptor on pituitary somatotrophs, driving GH synthesis, while Ipamorelin engages GHS-R1a, triggering selective GH release with negligible cortisol elevation. Consequently, the combination produces synergistic GH output through convergent but mechanistically independent pathways.

What is the composition of the blend?

The blend contains CJC-1295 (Mod GRF 1-29) 5mg and Ipamorelin 5mg for a total of 10mg.

What is the amino acid sequence of CJC-1295?

CJC-1295 is a 29-amino acid peptide: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It selectively stimulates GH release with negligible cortisol or prolactin elevation.

How does Ipamorelin differ from other GHRPs?

Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, whereas other GHRPs such as GHRP-2, GHRP-6, and Hexarelin generate robust GH output alongside measurable increases in ACTH, cortisol, and prolactin.

What evidence exists for the blend?

The synergistic effect of combining GHRH analogs with GHSs is well-established in the literature. CJC-1295 + Ipamorelin is frequently chosen for its favorable selectivity profile. Each peptide has been studied individually for its respective mechanisms.

Is the blend approved as a medicine?

No. Regulatory authorities have not approved the blend as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is the blend intended for human use?

No. The blend is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy the CJC-1295 & Ipamorelin Blend in Switzerland?

You can buy the CJC-1295 & Ipamorelin Blend in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate the quality of this blend?

Researchers should look for identity confirmation via mass spectrometry for each component, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in the CJC-1295 & Ipamorelin Blend may also find the following related compounds relevant to their work:

• CJC-1295 (Mod GRF 1-29) — Individual GHRH analog researched for GH synthesis and pulsatile secretion.
• Ipamorelin — Individual GHRP researched for selective GH release with minimal cortisol elevation.
• CJC-1295 & GHRP-2 Blend — Alternative GHRH/GHS blend with stronger GH release and more cortisol/prolactin elevation.
• CJC-1295 & GHRP-6 Blend — Alternative GHRH/GHS blend with significant appetite stimulation.

Explore Growth Hormone Peptides

The CJC-1295 & Ipamorelin Blend belongs to the Growth Hormone Peptides category of research compounds. Growth Hormone Peptides products are studied for their potential roles in GH axis signaling, metabolic regulation, and growth-related pathways. Generally, researchers who buy this blend in Switzerland often pair it with related compounds in this category to explore complementary pathways in GH research and metabolic studies.

Explore Growth Hormone Blends

Researchers studying multi-peptide GH axis signaling and synergistic GH release may also find relevant compounds in the Growth Hormone Blends subcategory. This blend’s combination of GHRH and selective GHS pathways makes it a valuable tool for investigating receptor pharmacology and convergent GH signaling.

Explore Muscle & Performance

Researchers studying muscle preservation, recovery, and performance-related mechanisms may also find relevant compounds in the Muscle & Performance category. The blend’s effects on GH-dependent anabolic signaling make it a valuable tool for investigating muscle function and recovery.

Further Research

For researchers seeking to deepen their understanding of the CJC-1295 & Ipamorelin Blend and its research applications, the following areas may warrant further investigation:

• The relationship between combined GHRH/GHS activity and specific downstream signaling pathways in different cell types
• Comparative studies between the CJC-1295/Ipamorelin blend and individual components in various GH axis and metabolic models
• The potential for Ipamorelin’s selective GH release profile to provide insights into isolated GH effects without adrenal axis activation
• Mechanistic studies on peptide stability and compatibility in blended systems
• Exploration of the blend’s effects on different tissue systems beyond musculoskeletal and metabolic models

Research Disclaimer

Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.